Contact Us
Drug Search Results
More Filters [+]

Midodrine

Alternative Names: midodrine, proamatine, Midodrinhydrochlorid, orvaten, gutron
Latest Update: 2024-12-12
Latest Update Note: Clinical Trial Update

Product Description

Midodrine is used to treat orthostatic hypotension (sudden fall in blood pressure that occurs when a person assumes a standing position). Midodrine is in a class of medications called alpha-adrenergic agonists. It works by causing blood vessels to tighten, which increases blood pressure. (Sourced from: https://medlineplus.gov/druginfo/meds/a616030.html)

Mechanisms of Action: ADRA1A Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bulgaria | Canada | Chile | Czech | Denmark | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Korea | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovenia | Spain | Sweden | Switzerland | Taiwan | United Arab Emirates | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Midodrine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

12/21/2023

News Article

 Mallinckrodt Announces Journal Publication of Economic Evidence for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS)

09/15/2023

News Article

 The global Isoprenaline market trends, applications, analysis, growth, and forecast predict that the market will grow at a CAGR of 12.5% from 2023 to 2030.

09/15/2023

News Article

 Methoxamine market size is anticipated to expand significantly over the projected period of 2023 to 2030 with a CAGR of 6.6%

09/15/2023

News Article

 Sympathomimetic Agents market research study will assist stakeholders in making more educated decisions by utilising a variety of tactics with a growing CAGR of 5.7%.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions